Can Clearside Biomedical, Inc. (CLSD)’s Tomorrow Be Different? The Stock Increases Again

April 17, 2018 - By Linda Rogers

The stock of Clearside Biomedical, Inc. (NASDAQ:CLSD) is a huge mover today! The stock increased 10.55% or $1.11 during the last trading session, reaching $11.63. About 693,325 shares traded. Clearside Biomedical, Inc. (NASDAQ:CLSD) has risen 41.83% since April 17, 2017 and is uptrending. It has outperformed by 30.28% the S&P500.
The move comes after 7 months positive chart setup for the $371.15 million company. It was reported on Apr, 17 by Barchart.com. We have $11.98 PT which if reached, will make NASDAQ:CLSD worth $11.13 million more.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. The company has market cap of $371.15 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion ; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). It currently has negative earnings. The companyÂ’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD).

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: